Phuong N. Huynh

Array ( [id] => 17126518 [patent_doc_number] => 20210301286 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-30 [patent_title] => TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES [patent_app_type] => utility [patent_app_number] => 17/332598 [patent_app_country] => US [patent_app_date] => 2021-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 77460 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17332598 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17214570 [patent_doc_number] => 20210347907 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => MODIFIED ANTIBODIES CONTAINING MODIFIED IGG2 DOMAINS WHICH ELICIT AGONIST OR ANTAGONISTIC PROPERTIES AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/327837 [patent_app_country] => US [patent_app_date] => 2021-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29835 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17327837 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19425072 [patent_doc_number] => 12084475 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-10 [patent_title] => Methods for site specific conjugation of proteins containing glycosylated Fc domains [patent_app_type] => utility [patent_app_number] => 17/324150 [patent_app_country] => US [patent_app_date] => 2021-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 14165 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 304 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17324150 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17227129 [patent_doc_number] => 20210353685 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-18 [patent_title] => Augmentation of Cell Therapy Efficacy by Inhibition of Complement Activation Pathways [patent_app_type] => utility [patent_app_number] => 17/320890 [patent_app_country] => US [patent_app_date] => 2021-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14554 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17320890 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18724388 [patent_doc_number] => 20230338533 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => Hypoimmunogenic Cells and Uses Thereof in Immune Responses [patent_app_type] => utility [patent_app_number] => 17/923070 [patent_app_country] => US [patent_app_date] => 2021-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4775 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17923070 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17297953 [patent_doc_number] => 20210393792 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => ANTIBODY-CONJUGATES FOR TARGETING OF TUMOURS EXPRESSING TROP-2 [patent_app_type] => utility [patent_app_number] => 17/307447 [patent_app_country] => US [patent_app_date] => 2021-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23051 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 156 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17307447 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17036746 [patent_doc_number] => 20210253704 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES [patent_app_type] => utility [patent_app_number] => 17/306079 [patent_app_country] => US [patent_app_date] => 2021-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46919 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -76 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17306079 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19839092 [patent_doc_number] => 12251448 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-18 [patent_title] => Compositions and methods for the depletion of CD5+ cells [patent_app_type] => utility [patent_app_number] => 17/244721 [patent_app_country] => US [patent_app_date] => 2021-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 42318 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 473 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17244721 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18582946 [patent_doc_number] => 20230265204 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => ENZYME AND PATHWAY MODULATION WITH SULFHYDRYL COMPOUNDS AND THEIR DERIVATIVES [patent_app_type] => utility [patent_app_number] => 17/996807 [patent_app_country] => US [patent_app_date] => 2021-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42865 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 187 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17996807 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17140231 [patent_doc_number] => 20210308242 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => FUSION PROTEINS COMPRISING AN ANTI-CD40 ANTIBODY AND CANCER ANTIGENS [patent_app_type] => utility [patent_app_number] => 17/301704 [patent_app_country] => US [patent_app_date] => 2021-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29757 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17301704 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17480688 [patent_doc_number] => 20220088192 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => COMPOSITIONS AND METHODS FOR CONJUGATING ACTIVATABLE ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/227004 [patent_app_country] => US [patent_app_date] => 2021-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41437 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17227004 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19318369 [patent_doc_number] => 20240239912 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-18 [patent_title] => TARGETED REDUCTION OF ACTIVATED IMMUNE CELLS [patent_app_type] => utility [patent_app_number] => 17/917523 [patent_app_country] => US [patent_app_date] => 2021-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23961 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17917523 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17170393 [patent_doc_number] => 20210324063 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-21 [patent_title] => ANTIBODIES AND CONJUGATES THEREOF [patent_app_type] => utility [patent_app_number] => 17/301599 [patent_app_country] => US [patent_app_date] => 2021-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35726 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17301599 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17036782 [patent_doc_number] => 20210253740 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => MODIFIED IMMUNOGLOBULIN HINGE REGIONS TO REDUCE HEMAGGLUTINATION [patent_app_type] => utility [patent_app_number] => 17/223778 [patent_app_country] => US [patent_app_date] => 2021-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9578 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17223778 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18418600 [patent_doc_number] => 20230173058 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => SARS-COV-2 VACCINE [patent_app_type] => utility [patent_app_number] => 17/922328 [patent_app_country] => US [patent_app_date] => 2021-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4629 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17922328 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20788641 [patent_doc_number] => 12662546 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-06-23 [patent_title] => Human anti-CD33 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 17/907655 [patent_app_country] => US [patent_app_date] => 2021-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 18 [patent_no_of_words] => 27594 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 349 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17907655 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18376033 [patent_doc_number] => 20230151115 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-18 [patent_title] => MULTISPECIFIC ANTIBODY AND METHOD FOR PRODUCING SAME [patent_app_type] => utility [patent_app_number] => 17/907659 [patent_app_country] => US [patent_app_date] => 2021-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17859 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17907659 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17156161 [patent_doc_number] => 20210317212 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs [patent_app_type] => utility [patent_app_number] => 17/207526 [patent_app_country] => US [patent_app_date] => 2021-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43215 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17207526 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16932757 [patent_doc_number] => 20210198646 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-01 [patent_title] => METHODS TO CREATE CHEMICALLY-INDUCED DIMERIZING PROTEIN SYSTEMS FOR REGULATION OF CELLULAR EVENTS [patent_app_type] => utility [patent_app_number] => 17/203473 [patent_app_country] => US [patent_app_date] => 2021-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20475 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17203473 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17067319 [patent_doc_number] => 20210269534 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => FLT3 DIRECTED CAR CELLS FOR IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/199332 [patent_app_country] => US [patent_app_date] => 2021-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34163 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17199332 [rel_patent_id] =>[rel_patent_doc_number] =>)